Phase II study of 5-fluorouracil and leucovorin in recurrent primary brain tumor.
Thirty patients with recurrent primary brain tumors were treated with a combination of 5-fluorouracil and leucovorin. There were three responses seen. Toxicity consisted of stomatitis, diarrhea, and hematological suppression. 5-fluorouracil and leucovorin would appear to be minimally effective in recurrent brain tumors.
Cascino
T L
TL
Mayo Clinic, Rochester, MN 55905, USA.
Veeder
M H
MH
Buckner
J C
JC
O'Fallon
J R
JR
Wiesenfeld
M
M
Levitt
R
R
Goldberg
R M
RM
Kuross
S A
SA
Morton
R F
RF
Scheithauer
B W
BW
D000328:Adult; D000368:Aged; D000931:Antidotes / Q000627:therapeutic use* / Q000633:toxicity; D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use* / Q000633:toxicity; D001254:Astrocytoma / Q000188:drug therapy*; D001932:Brain Neoplasms / Q000188:drug therapy*; D005260:Female; D005472:Fluorouracil / Q000627:therapeutic use* / Q000633:toxicity; D006801:Humans; D002955:Leucovorin / Q000627:therapeutic use* / Q000633:toxicity; D007970:Leukopenia / Q000139:chemically induced; D008297:Male; D008875:Middle Aged; D009837:Oligodendroglioma / Q000188:drug therapy*; D012008:Recurrence; D013280:Stomatitis / Q000139:chemically induced; D013921:Thrombocytopenia / Q000139:chemically induced
D000931:Antidotes; D000964:Antimetabolites, Antineoplastic; D002955:Leucovorin; D005472:Fluorouracil